Fig. 2From: The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts a TGFβ ELISA in lung CAFs treated for 72 h with pirfenidone (1.5 mg/mL). Decreased TGFβ is observed in lung CAFs in the presence of pirfenidone. b MTS assay showed viability of lung CAFs after 72-h treatment with pirfenidone (Pirf; 1.5 mg/mL) in the presence and absence of rhTGFβ (TGFβ, 5 ng/mL). *P < 0.05Back to article page